Crystalline HCl Salt Form of Compound A for Stable Solid Dosage
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing methods for preparing Compound A, a selective CB2 receptor agonist, result in a non-crystalline free base form that is not suitable for drug development and formulation, lacking stability and suitable solubility characteristics.
Innovation Solution
The development of a hydrochloric acid (HCl) salt of Compound A in specific crystalline forms, characterized by distinct X-ray diffraction patterns and melting points, which are stable and suitable for pharmaceutical compositions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Stability of the object's composition
If the free base form of Compound A is prepared using existing methods, then the compound can be obtained, but it lacks crystallinity and stability required for pharmaceutical development
Solution Approach 1:
The patent applies parameter changes by converting the free base form of Compound A into a hydrochloric acid salt form. This chemical parameter change (from free base to salt) fundamentally alters the physical properties of the compound, enabling it to achieve both crystallinity and stability. The salt formation process changes the molecular state and intermolecular interactions, resulting in a stable crystalline structure suitable for pharmaceutical development.
Solution Approach 2:
The patent utilizes phase transitions by transforming the compound from an amorphous free base state to a crystalline salt state. This phase transition is achieved through salt formation with hydrochloric acid, which reorganizes the molecular arrangement into a structured crystal lattice. The resulting crystalline form exhibits defined melting points and stable physical properties, resolving the contradiction between stability and crystallinity.
2Ease of manufacture
If the free base form is used, then synthesis is straightforward, but the product is not suitable for solid dosage forms due to lack of crystallinity
Solution Approach 1:
The patent maintains ease of manufacture by using a simple salt formation process with hydrochloric acid, which is a straightforward chemical transformation.同时，it achieves manufacturing precision by producing a well-defined crystalline salt form with specific XRPD patterns and melting points. The salt formation step is easily incorporated into existing synthesis routes while dramatically improving the crystalline quality required for solid dosage forms.
3Stability of the object's composition
If a crystalline form is achieved through salt formation, then stability and crystallinity improve, but additional processing steps are required
Solution Approach 1:
The patent achieves stability and crystallinity through a single phase transition step - salt formation with hydrochloric acid. This one-step transformation converts the amorphous free base into a stable crystalline salt, avoiding the need for multiple complex processing steps such as repeated recrystallization or solvent removal. The simplicity of this phase transition approach minimizes process complexity while maximizing product quality.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The HCl salt of Compound A in crystalline forms provides a stable and effective pharmaceutical composition, suitable for solid dosage forms, with improved stability and solubility, enabling effective treatment of various medical conditions mediated by CB2 receptor activity.
Implementation Method 1
The development of a hydrochloric acid (HCl) salt of Compound A in crystalline form, characterized by specific XRPD patterns and high melting points
Data Source
AI summary
A salt of 2-[3-({1-[2-(dimethylamino)ethyl]-2-(2,2-dimethylpropyl)-1H-1,3-benzodiazol-5-yl}sulfonyl)azetidin-1-yl]ethan-1-ol with an acid, wherein the acid is selected from the group consisting of hydrochloric acid (HCl), maleic acid, and methanesulfonic acid; a crystalline form of the salt; a pharmaceutical composition comprising the salt; a pharmaceutical composition comprising the crystalline form; a method for preventing or treating a disorder or condition comprising administering the salt; and a process for preparing a pharmaceutically acceptable salt.